Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00219089 · ClinicalTrials.gov registry record · Phase 3
A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.
A Phase 3 study of Hypertension, Diabetes Mellitus, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 839
- Enrollment target
- 2
- Study locations
NCT00219089 is a Phase 3 study of Hypertension, Diabetes Mellitus that has completed, run by Novartis. The registered enrollment target is 839 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT00219089, a Phase 3 study of Hypertension, Diabetes Mellitus, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 839 participants
- Enrollment target
- 2
- Study locations
Study Summary
To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus
Conditions Studied
Interventions
- DRUG aliskiren
Study Locations (2)
New Jersey
- Novartis Pharmaceuticals - East Hanover
Other
- - Investigative Centers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 839 participants |
| Start Date | 2004-11 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00219089
The ClinicalTrials.gov registry entry for NCT00219089 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 839 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypertension, Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which aliskiren is the first listed.
NCT00219089 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Other.
Frequently Asked Questions
What is clinical trial NCT00219089 about?
NCT00219089 is a clinical study titled "A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.". To demonstrate the efficacy and safety of aliskiren given to patients with both hypertension and diabetes mellitus
What is the current status of trial NCT00219089?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 839 participants. The study started on 2004-11. Estimated completion is 2005-08.
What conditions does trial NCT00219089 study?
This clinical trial studies the following conditions: Hypertension, Diabetes Mellitus.
What interventions are being tested in trial NCT00219089?
The interventions under investigation include: aliskiren (DRUG).
Who is sponsoring clinical trial NCT00219089?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00219089 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.